21. November 2009 00:50
Using highly precise measurements of plasma lipoprotein concentrations determined by nuclear magnetic resonance spectroscopy (NMR), researchers led by Daniel Chasman at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, the Framingham Heart Study in Framingham, and the PROCARDIS consortium in Stockholm, Sweden and Oxford, England performed genetic association analysis across the whole genome among 17,296 women of European ancestry from the Women's Genome Health Study.
[More]
20. November 2009 01:25
Today, Jamieson Laboratories, in partnership with the Victorian Order of Nurses (VON), is holding a one day Blood Pressure Blitz in Toronto's underground PATH system in an effort to educate consumers about the number one risk factor for stroke and a major risk factor of heart disease.
[More]
d0a21bf4-35f6-47ca-828b-780b6397e3e1|0|.0
Posted in: Medical Condition News
Tags: Atorvastatin, Blood Pressure, Cardiovascular Disease, Cholesterol, Dentistry, Diet, Education, Exercise, Lipoprotein, Pharmacology, Rosuvastatin, Smoking, Statin, Stroke, Toxicology, Vitamin D
18. November 2009 05:33
In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.
[More]
18. November 2009 05:05
A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.
[More]
c902b942-aa3a-42cb-aa84-2bbe56fad227|0|.0
Posted in: Medical Condition News | Women's Health News | Pharmaceutical News
Tags: Angina, Atherosclerosis, Breast Cancer, Calcium, Cancer, Cardiology, Cardiovascular Disease, Cholesterol, Coronary Heart Disease, Diet, Lipoprotein, Neuroscience, Oncology, Rosuvastatin, Smoking, Statin, Stroke
18. November 2009 04:53
Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.
[More]
18. November 2009 04:03
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.
[More]
17. November 2009 10:42
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.
[More]
1a400a77-bfd0-472a-9ee1-b2297389c9de|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antisense, Atherosclerosis, Biotechnology, Cancer, Carbohydrate, Cardiovascular Disease, Cholesterol, Coronary Heart Disease, Hypercholesterolemia, Kidney Disease, Lipids, Lipoprotein, Metabolism, microRNA, Statin, Transplant
17. November 2009 04:29
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
[More]
66ace4d3-8c30-4f54-aa13-bc14652022b0|0|.0
Posted in: Device / Technology News | Medical Condition News
Tags: Angiotensin, Atherosclerosis, Biomarker, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Hospital, Lipoprotein, Pathology, Stenosis, Stroke, Trandolapril
17. November 2009 04:10
Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.
[More]
fb3789c9-4d82-442c-a5f1-72d2e21cad7b|0|.0
Posted in: Medical Condition News | Miscellaneous News
Tags: Anti-Inflammatory, Antioxidant, Atherosclerosis, Atorvastatin, Brain, Calcium, Cholesterol, Hyperlipidemia, Lipoprotein, Myopathy, Pfizer, Statin, Stroke, Triglyceride
16. November 2009 11:17
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
[More]
16. November 2009 05:56
In combination with statins, adding a medication that raises high-density lipoprotein (HDL) cholesterol was more effective in reversing artery wall plaque buildup and in reducing heart disease risk than adding a drug that lowers low-density lipoprotein (LDL) cholesterol, researchers reported today at the American Heart Association Scientific Sessions 2009.
[More]
13. November 2009 01:45
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
[More]
16a7012b-d78f-446e-9b5b-14867f97637f|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anti-Inflammatory, Atherosclerosis, Atorvastatin, Cholesterol, Coronary Heart Disease, Lipoprotein, New Drug Application, Nitric Oxide, Osteoarthritis, Stroke, Thrombosis
11. November 2009 04:51
Lipid assessment in vascular disease can be simplified by measuring either total and HDL cholesterol levels or apolipoproteins, without the need to fast and without regard to triglyceride levels, according to a study in the November 11 issue of JAMA.
[More]
5. November 2009 07:41
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.
[More]
731d501d-753a-4b06-a250-b0868714e3b3|0|.0
Posted in: Business / Finance | Medical Science News
Tags: Antisense, Biochemistry, Cell, Cholesterol, Gene Expression, Hepatocellular Carcinoma, Herpes, Herpes Simplex, Herpes Simplex Virus-2, Hypercholesterolemia, Lipoprotein, Metabolism, Microbicide, microRNA, Nanoparticle, Oncology, Pediatrics, Pharmacology, Physiology, RNAi Therapeutics, siRNA, VEGF, Virus
29. October 2009 10:30
The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.
[More]
2a407067-7739-4ad8-9008-e3ffcba33e78|0|.0
Posted in: Medical Condition News
Tags: Arthritis, Atherosclerosis, Atorvastatin, Blood Pressure, Cardiology, Cardiovascular Disease, Cholesterol, Coronary Artery Disease, Coronary Heart Disease, Diabetes, Diabetes Mellitus, Diet, Dyslipidemia, Headache, Heart Failure, Hypercholesterolemia, Kidney Disease, Lipoprotein, Metabolic Syndrome, Obesity, Pfizer, Psoriasis, Rheumatoid Arthritis, Smoking, Statin, Stroke, Type 2 Diabetes
Subscribe